ENHERTU yemereye Ubuvuzi bw'Iterambere mu Bushinwa kubera Kanseri y'ibere ya HER2+ ifite ibyago byinshi - Amakuru y'inyongera agaragaza inyungu ya IDFS ya 53%

Ku ya 12 Gashyantare 2026, Ikigo cy’Isuzuma ry’Imiti (CDE) cy’Ikigo cy’Igihugu cy’Ubuvuzi mu Bushinwa cyatangaje ku ya 4 Gashyantare ko ENHERTU® (trastuzumab deruxtecan) yatanzweho igitekerezo cyo gushyirwa muri Gahunda yo Gutanga Ubuvuzi bw’Iterambere kugira ngo ikoreshwe nk’ubuvuzi bwunganira abarwayi bakuru bafite kanseri y’ibere ya HER2 bakiri bato bafite indwara isigaye nyuma yo kuvura HER2 ya neoadjuvant. Iki cyemezo gishingiye ku makuru y’ubushakashatsi bwa DESTINY-Breast05 Phase III, bwatanzwe mu Nama Nkuru ya ESMO yo mu 2025, yagaragaje ko ENHERTU yagabanyije ibyago byo kubaho cyangwa gupfa ku kigero cya 53% ugereranije na T-DM1.

ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki muri Amerika gusa) ni ADC iyobowe na HER2. Yakozwe hifashishijwe ikoranabuhanga rya Daiichi Sankyo rya DXd ADC, ENHERTU niyo ADC iyoboye mu bushakashatsi bwa oncology bwa Daiichi Sankyo kandi ikaba ari na gahunda igezweho cyane mu bushakashatsi bwa ADC bwa AstraZeneca. ENHERTU igizwe na antibody ya monoclonal ya HER2 ifatanye n'imiti myinshi ya topoisomerase I inhibitor payloads (ikomoka kuri exatecan, DXd) binyuze mu miyoboro ihuza ingirabuzimafatizo ishingiye kuri tetrapeptide.

DESTINY-Breast05 ni igerageza ryakozwe ku rwego rw'isi, ryihariye, ryihariye, ry’icyiciro cya 3, risuzuma imikorere n'umutekano wa ENHERTU (5.4 mg/kg) ugereranije na trastuzumab emtansine (T-DM1) ku barwayi ba kanseri y'ibere ya HER2 barwaye kanseri y'ibere mu ntangiriro z'ikigero cy'indwara isigaye mu mabere cyangwa mu dusabo tw'inkondo nyuma yo kuvurwa na neoadjuvant ndetse n'ibyago byinshi byo kugaruka. Ibyago byinshi byo kugaruka byasobanuwe nko kugaragaza kanseri idakira (mbere yo kuvurwa na neoadjuvant) cyangwa lymph nodes z'inkondo nyuma yo kuvurwa na neoadjuvant.

Amakuru y'ingenzi yavuye mu bushakashatsi bwa DESTINY-Breast05:
- Kurokoka kutagira indwara (IDFS): Igipimo cya IDFS cy'imyaka itatu cyari 92.4% mu gice cya ENHERTU ugereranyije na 83.7% mu gice cyagenwe (T-DM1), bigaragaza ko ibyago byagabanutseho 53% (HR = 0.47).
- Kurokoka kutagira indwara (DFS): Igipimo cya DFS cy'imyaka itatu cyari 92.3% mu gice cya ENHERTU ugereranyije na 83.5% mu gice cyagenzurwaga, nabyo bigaragaza kugabanuka kw'ibyago kuri 53% (HR = 0.47).
- Ingaruka zo Kugaruka kwa Gake (DRFI): Zagabanutseho 51%, aho igipimo cya DRFI mu myaka itatu cya 93.9% ugereranije na 86.1%.
- Ingaruka zo kurwara ubwonko (BMFI): Zagabanutseho 36%, hamwe n'igipimo cya BMFI mu myaka itatu cya 97.6% ugereranije na 95.8%.

Ishami Mpuzamahanga ry’Ibitaro bya Kanseri bya Beijing Southern Suburb ryiyemeje gufasha abarwayi bo mu mahanga, ritanga ubufasha mu ndimi zitandukanye, gutanga amafaranga y’ubwishingizi mpuzamahanga, guherekeza abarwayi ku giti cyabo, na serivisi zo gusabana kuri telefoni. Ku barwayi ba kanseri y’ibere ya HER2, Ishami Mpuzamahanga ritanga itsinda ry’abaganga bakuru ba kanseri kugira ngo bategure gahunda z’ubuvuzi bw’inyongera ku giti cyabo.

Shaka ubu ngubu kugira ngo umenye uko wavurwa:
Telefoni Mpuzamahanga ishinzwe abarwayi: 400-880-3716 (serivisi y'amasaha 24 mu ndimi ebyiri, Igishinwa/Icyongereza)
Umurongo wa WeChat: 17801183037
Official Email ①: 100085_010@163.com
Backup Email ②: myimmnet@163.com

Waba uri umurwayi uherutse gufatwa n’indwara ushaka ingamba zo kuvura indwara zisigaye nyuma yo kuvurwa na neoadjuvant, cyangwa umurwayi wabazwe kandi akaba arimo gutekereza ku buryo bwo kuvura budasanzwe, itsinda ry’Ishami Mpuzamahanga rishobora kurangiza isuzuma ry’ibanze ry’inyandiko z’ubuvuzi vuba kandi rigatanga inama zanditse ku kuvura.